Antineoplastic Agents, Hormonal

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. 
  • A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. 
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials. 
  • A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. 
  • A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. 
  • A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. 
  • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. 
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. 
  • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. 
  • Adenocarcinoma of the prostate: an expensive way to die. 
  • Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. 
  • Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 
  • Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. 
  • Adjuvant hormonal therapy use among insured, low-income women with breast cancer. 
  • Adjuvant hormonal therapy use among women with ductal carcinoma in situ. 
  • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. 
  • Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified? 
  • Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. 
  • Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. 
  • Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. 
  • Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Breast cancer in older women. 
  • Burden of disease matters when it comes to systemic therapy for prostate cancer. 
  • Cell cycle regulation of human pancreatic cancer by tamoxifen. 
  • Cell lineage mapping of taste bud cells and keratinocytes in the mouse tongue and soft palate. 
  • Chromatographic analysis and decomposition product characterization of compound SR16157 (NSC 732011). 
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. 
  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. 
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). 
  • Combination hormonal therapy: a reassessment within advanced prostate cancer. 
  • Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. 
  • Contemporary hormonal management of advanced prostate cancer. 
  • Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? 
  • Current Trends in the Management of Ductal Carcinoma In Situ. 
  • Current status of endocrine therapy for metastatic breast cancer. 
  • Dedifferentiation of committed epithelial cells into stem cells in vivo. 
  • Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression. 
  • ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. 
  • Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. 
  • Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. 
  • Effect of vitamin E on tamoxifen-treated breast cancer cells. 
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
  • Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. 
  • Endocrine therapy in early-stage breast cancer care: defining the appropriate regimen and time frame. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Estrogen-related receptor alpha as a therapeutic target in cancer. 
  • Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. 
  • Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Focusing on testosterone. 
  • Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. 
  • Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. 
  • Gestational dexamethasone treatment elicits sex-dependent alterations in locomotor activity, reward-based memory and hippocampal cholinergic function in adolescent and adult rats. 
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. 
  • Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. 
  • Hormonal treatment of an endometrial stromal nodule followed by local excision. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Hormone refractory prostate cancer: Management and advances. 
  • How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. 
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. 
  • Improving understanding of adjuvant therapy options by using simpler risk graphics. 
  • Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. 
  • Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. 
  • Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Isolated tumor cells in breast cancer. 
  • Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. 
  • Late GI and GU complications in the treatment of prostate cancer. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Management of ductal carcinoma in situ. 
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 
  • Managing advanced prostate cancer with Viadur (leuprolide acetate implant). 
  • Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. 
  • Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. 
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Multiple endocrine neoplasia type 1 manifesting with chronic and persistent diarrhea. 
  • Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy. 
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. 
  • Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. 
  • Neoadjuvant hormone therapy: the Canadian trials. 
  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • New drugs in prostate cancer. 
  • New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps? 
  • Next-Generation Endocrine Therapies for Breast Cancer. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours. 
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 
  • Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. 
  • Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. 
  • Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. 
  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. 
  • Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. 
  • Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. 
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. 
  • Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 
  • Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. 
  • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. 
  • Progress in breast cancer-can we do better? 
  • Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. 
  • Prostate specific antigen recurrence after definitive therapy. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. 
  • Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 
  • Prostatectomy vs brachytherapy for localized prostate cancer. 
  • Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. 
  • Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. 
  • Racial and ethnic differences in adjuvant hormonal therapy use. 
  • Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 
  • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
  • Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. 
  • Recent advances in the treatment of prostate cancer. 
  • Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Report from Durham. 
  • Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. 
  • Rising PSA in nonmetastatic prostate cancer. 
  • Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. 
  • Safety of octreotide in hospitalized infants. 
  • Screening experiments and the use of fractional factorial designs in behavioral intervention research. 
  • Second-line chemotherapy for advanced hormone-refractory prostate cancer. 
  • Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis. 
  • Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. 
  • Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. 
  • Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. 
  • Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). 
  • Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. 
  • Systemic strategies for prostate cancer. 
  • Systemic therapy for older women with breast cancer. 
  • Systemic therapy for prostate cancer. 
  • Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). 
  • The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. 
  • The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. 
  • The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. 
  • The benefits of discussing adjuvant therapies one at a time instead of all at once. 
  • The effect of dexamethasone on the generation of plasma DNA from dead and dying cells. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer. 
  • The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. 
  • Time for a neoadjuvant chemotherapy strategy in prostate cancer? 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Towards Prevention of Breast Cancer: What Are the Clinical Challenges? 
  • Traditional approaches to androgen deprivation therapy. 
  • Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • Twenty-five year evolution of medical hormonal therapy for prostate cancer. 
  • Update in the management of patients with hormone-refractory prostate cancer. 
  • Variations in cancer care for adolescents and young adults (AYAs) with ductal carcinoma in situ. 
  • Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. 
  • Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • Women's interest in chemoprevention for breast cancer. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology